JP2009544688A - 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 - Google Patents

虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 Download PDF

Info

Publication number
JP2009544688A
JP2009544688A JP2009521380A JP2009521380A JP2009544688A JP 2009544688 A JP2009544688 A JP 2009544688A JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009544688 A JP2009544688 A JP 2009544688A
Authority
JP
Japan
Prior art keywords
polypeptide
fusion polypeptide
seq
phospholipase
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544688A5 (enrdf_load_stackoverflow
Inventor
サンギュ イ
キチョル ファン
スンギュ イ
ヤンス ジャン
Original Assignee
フォーヒューマンテック カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォーヒューマンテック カンパニー リミテッド filed Critical フォーヒューマンテック カンパニー リミテッド
Publication of JP2009544688A publication Critical patent/JP2009544688A/ja
Publication of JP2009544688A5 publication Critical patent/JP2009544688A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009521380A 2006-07-24 2007-07-19 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 Pending JP2009544688A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83258406P 2006-07-24 2006-07-24
PCT/IB2007/003404 WO2008015580A2 (en) 2006-07-24 2007-07-19 Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same

Publications (2)

Publication Number Publication Date
JP2009544688A true JP2009544688A (ja) 2009-12-17
JP2009544688A5 JP2009544688A5 (enrdf_load_stackoverflow) 2010-08-05

Family

ID=38997534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521380A Pending JP2009544688A (ja) 2006-07-24 2007-07-19 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法

Country Status (6)

Country Link
US (1) US7902154B2 (enrdf_load_stackoverflow)
EP (1) EP2044108A4 (enrdf_load_stackoverflow)
JP (1) JP2009544688A (enrdf_load_stackoverflow)
KR (1) KR101574630B1 (enrdf_load_stackoverflow)
CN (1) CN101490080A (enrdf_load_stackoverflow)
WO (1) WO2008015580A2 (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134063A2 (en) * 2007-04-27 2008-11-06 The University Of North Carolina At Chapel Hill Activated lipases and methods of use therefor
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
CN101612384B (zh) * 2009-07-23 2012-06-20 中国人民解放军第二军医大学 多肽小分子mlif在制备防治心肌缺血药物中的应用
KR101278221B1 (ko) 2010-06-01 2013-06-24 연세대학교 산학협력단 Ρtd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
US9844584B2 (en) 2012-05-11 2017-12-19 Gemvax & Kael Co., Ltd. Composition for preventing or treating sepsis
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
JP6474786B2 (ja) 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー,リミティド 虚血性損傷の治療及び予防用の組成物
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015167067A1 (ko) * 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー,リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
ES2886946T3 (es) 2015-07-02 2021-12-21 Gemvax & Kael Co Ltd Péptido con efecto antiviral y composición que lo contiene
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
KR20250057224A (ko) 2023-10-19 2025-04-29 단국대학교 천안캠퍼스 산학협력단 Pdrn을 이용한 유치줄기세포를 포함하는 세포치료제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512275A (ja) * 2000-08-25 2004-04-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 膜透過性ペプチドおよびその使用
WO2004078933A2 (en) * 2003-03-04 2004-09-16 Biowhittaker Technologies Inc. Intracellular delivery of small molecules proteins and nucleic acids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4328397A (en) * 1996-08-23 1998-03-06 Chiron Corporation Human polyhomeotic 1 ((hph1)) acts as an oncogene
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 mph1-btm 및 이것을포함하는 생명공학제품
KR20030062789A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 sim2-btm 및 이것을포함하는 생명공학제품
KR100591936B1 (ko) 2002-11-12 2006-06-22 포휴먼텍(주) 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용
EP1625149B1 (en) * 2003-05-01 2016-02-17 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2004113497A2 (en) * 2003-06-09 2004-12-29 University Of Florida Gene delivery to tumors
KR20080084937A (ko) * 2005-11-04 2008-09-22 포휴먼텍(주) 융합 폴리펩타이드를 세포로 전달하는 방법
WO2008047243A2 (en) * 2006-08-29 2008-04-24 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512275A (ja) * 2000-08-25 2004-04-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 膜透過性ペプチドおよびその使用
WO2004078933A2 (en) * 2003-03-04 2004-09-16 Biowhittaker Technologies Inc. Intracellular delivery of small molecules proteins and nucleic acids

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
JPN6012053071; Arch. Biochem. Biophys. Vol.411, 2003, P.174-182 *
JPN6012053075; Nat. Med. Vol.10, No.3, 2004, P.305-309 *
JPN6012053079; Neurosci. Lett. Vol.368, 2004, P.258-262 *
JPN6012053081; Biochem. Biophys. Res. Commun. Vol.346, 200605, P.1-6 *
JPN6012053082; Ann. Surg. Onc. Vol.12, No.7, 2005, P.1-9 *
JPN7012004148; Br. J. Cancer Vol.90, 2004, P.230-235 *
JPN7012004149; J. Cell. Biochem. Vol.97, 200602, P.233-243 *
JPN7012004150; Am. J. Physiol. Heart Circ. Physiol. Vol.291, 200602, P.H854-H860 *
JPN7012004151; Am. J. Physiol. Heart Circ. Physiol. Vol.287, 2004, P.H719-H727 *
JPN7012004153; Mol. Cell. Neurosci. Vol.21, 2002, P.29-37 *
JPN7012004155; TiPS Vol.21, 2000, P.45-48 *
JPN7012004159; J. Neurosci. Vol.22, No.13, 2002, P.5423-5431 *
JPN7012004160; Hypertension Vol.41, 2003, P.751-756 *

Also Published As

Publication number Publication date
US7902154B2 (en) 2011-03-08
EP2044108A4 (en) 2010-06-30
US20090087422A1 (en) 2009-04-02
WO2008015580A3 (en) 2008-06-26
CN101490080A (zh) 2009-07-22
KR101574630B1 (ko) 2015-12-07
WO2008015580A2 (en) 2008-02-07
KR20090033878A (ko) 2009-04-06
EP2044108A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
JP2009544688A (ja) 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法
US20080132450A1 (en) Pharmaceutical composition for suppression of apoptosis and method for delivering the same
JP6948250B2 (ja) Larファミリーホスファターゼの活性を阻害する組成物及び方法
KR100966232B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
ES2400920T3 (es) Péptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminación o la destrucción de células
MXPA04004489A (es) Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
US6924266B2 (en) NTP-peptides and method for removal of tumors
US12171834B2 (en) Compositions and methods for inhibiting the activity of LAR family phosphatases
KR101695980B1 (ko) 세포 투과성 펩타이드
CN100537602C (zh) Ec sod和细胞转导性ec sod及它们的用途
US10479816B2 (en) Decoy peptides inhibiting protein phosphatase 1-medicated dephosphorylation of phospholamban
AU2017296189A1 (en) Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
US20150133388A1 (en) Acetylated crystallin polypeptides and mimetics thereof as therapeutic agents
HK1207303B (en) Compositions for use in treating neural injury by inhibiting the activity of lar family phosphatases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130924